Methods of treating prader-willi syndrome with carbetocin
US10967040B2 · kind B2 · utility
0Cited by
17References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 24, 2020 |
| Grant date | Apr 6, 2021 |
| Priority date | — |
| Expiry date | Jul 24, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.